Cargando…

Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial

BACKGROUND: Stroke is the primary cause of disability worldwide, the second most common cause of dementia and the third leading cause of death. Only few studies were conducted to study the role of fluoxetine in motor recovery in either ischemic or hemorrhagic stroke patients with probably less sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Karthickeyan, K, Muthuraj, K, Nandhini, Teja, Yalamanchili Dharma, Reddy, Vikrama Simha, Raju, Neethu Sara, Rathinam, Kiran Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264525/
https://www.ncbi.nlm.nih.gov/pubmed/34278042
http://dx.doi.org/10.1016/j.conctc.2021.100800
_version_ 1783719577450971136
author Krishnan, Karthickeyan
K, Muthuraj
K, Nandhini
Teja, Yalamanchili Dharma
Reddy, Vikrama Simha
Raju, Neethu Sara
Rathinam, Kiran Kumar
author_facet Krishnan, Karthickeyan
K, Muthuraj
K, Nandhini
Teja, Yalamanchili Dharma
Reddy, Vikrama Simha
Raju, Neethu Sara
Rathinam, Kiran Kumar
author_sort Krishnan, Karthickeyan
collection PubMed
description BACKGROUND: Stroke is the primary cause of disability worldwide, the second most common cause of dementia and the third leading cause of death. Only few studies were conducted to study the role of fluoxetine in motor recovery in either ischemic or hemorrhagic stroke patients with probably less severe paresis. However, the current study evaluates both the effectiveness and safety of fluoxetine in the stroke population with a more severe motor deficit. METHODS: Patients who had acute or subacute stroke with hemiparesis and aged between 18 and 80 years with medical research council (MRC) scale score <4 were included in this randomized, Single-blind, placebo-controlled trial in 1:1 ratio to placebo or fluoxetine 20 mg/day orally for 90 days. The primary outcome measures were changes in barthel index, time taken to complete nine hole peg test and number of hand tapping movements in 30 s by the affected limb between baseline, 45th day and 90th day. The secondary outcome measure was evaluation of the drug tolerability. RESULTS: A total of 168 patients were assigned to fluoxetine (n = 84) or placebo (n = 84) group. Mean BI score significantly improved at 90th day in fluoxetine group (70.42 ± 10.56) than in placebo group (44.23 ± 8.52). Mean dexterity value decreased significantly at 90th day (2.61 ± 0.81) compared to baseline (3.98 ± 0.53) in fluoxetine group. However higher rate of decrease of mean dexterity value was seen in fluoxetine group when compared to placebo group. Mean number of hands tapping movements in 30 s increased significantly at 90th day (16.33 ± 3.58) compared to baseline (9.83 ± 2.92) in fluoxetine group. Few ADR reported during this study were dizziness, drowsiness and insomnia. CONCLUSION: The present study indicates that early prescription of fluoxetine is safe and may enhance motor function in patients presenting with severe motor impairments after stroke. However, the findings of the study should be confirmed in future controlled studies with large sample size.
format Online
Article
Text
id pubmed-8264525
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82645252021-07-16 Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial Krishnan, Karthickeyan K, Muthuraj K, Nandhini Teja, Yalamanchili Dharma Reddy, Vikrama Simha Raju, Neethu Sara Rathinam, Kiran Kumar Contemp Clin Trials Commun Article BACKGROUND: Stroke is the primary cause of disability worldwide, the second most common cause of dementia and the third leading cause of death. Only few studies were conducted to study the role of fluoxetine in motor recovery in either ischemic or hemorrhagic stroke patients with probably less severe paresis. However, the current study evaluates both the effectiveness and safety of fluoxetine in the stroke population with a more severe motor deficit. METHODS: Patients who had acute or subacute stroke with hemiparesis and aged between 18 and 80 years with medical research council (MRC) scale score <4 were included in this randomized, Single-blind, placebo-controlled trial in 1:1 ratio to placebo or fluoxetine 20 mg/day orally for 90 days. The primary outcome measures were changes in barthel index, time taken to complete nine hole peg test and number of hand tapping movements in 30 s by the affected limb between baseline, 45th day and 90th day. The secondary outcome measure was evaluation of the drug tolerability. RESULTS: A total of 168 patients were assigned to fluoxetine (n = 84) or placebo (n = 84) group. Mean BI score significantly improved at 90th day in fluoxetine group (70.42 ± 10.56) than in placebo group (44.23 ± 8.52). Mean dexterity value decreased significantly at 90th day (2.61 ± 0.81) compared to baseline (3.98 ± 0.53) in fluoxetine group. However higher rate of decrease of mean dexterity value was seen in fluoxetine group when compared to placebo group. Mean number of hands tapping movements in 30 s increased significantly at 90th day (16.33 ± 3.58) compared to baseline (9.83 ± 2.92) in fluoxetine group. Few ADR reported during this study were dizziness, drowsiness and insomnia. CONCLUSION: The present study indicates that early prescription of fluoxetine is safe and may enhance motor function in patients presenting with severe motor impairments after stroke. However, the findings of the study should be confirmed in future controlled studies with large sample size. Elsevier 2021-06-24 /pmc/articles/PMC8264525/ /pubmed/34278042 http://dx.doi.org/10.1016/j.conctc.2021.100800 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Krishnan, Karthickeyan
K, Muthuraj
K, Nandhini
Teja, Yalamanchili Dharma
Reddy, Vikrama Simha
Raju, Neethu Sara
Rathinam, Kiran Kumar
Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial
title Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial
title_full Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial
title_fullStr Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial
title_full_unstemmed Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial
title_short Role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: A randomized, placebo-controlled, single-blind trial
title_sort role of fluoxetine in pharmacological enhancement of motor functions in stroke patients: a randomized, placebo-controlled, single-blind trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264525/
https://www.ncbi.nlm.nih.gov/pubmed/34278042
http://dx.doi.org/10.1016/j.conctc.2021.100800
work_keys_str_mv AT krishnankarthickeyan roleoffluoxetineinpharmacologicalenhancementofmotorfunctionsinstrokepatientsarandomizedplacebocontrolledsingleblindtrial
AT kmuthuraj roleoffluoxetineinpharmacologicalenhancementofmotorfunctionsinstrokepatientsarandomizedplacebocontrolledsingleblindtrial
AT knandhini roleoffluoxetineinpharmacologicalenhancementofmotorfunctionsinstrokepatientsarandomizedplacebocontrolledsingleblindtrial
AT tejayalamanchilidharma roleoffluoxetineinpharmacologicalenhancementofmotorfunctionsinstrokepatientsarandomizedplacebocontrolledsingleblindtrial
AT reddyvikramasimha roleoffluoxetineinpharmacologicalenhancementofmotorfunctionsinstrokepatientsarandomizedplacebocontrolledsingleblindtrial
AT rajuneethusara roleoffluoxetineinpharmacologicalenhancementofmotorfunctionsinstrokepatientsarandomizedplacebocontrolledsingleblindtrial
AT rathinamkirankumar roleoffluoxetineinpharmacologicalenhancementofmotorfunctionsinstrokepatientsarandomizedplacebocontrolledsingleblindtrial